Physician profile
Daniel Diamond
NPI 1730666058
$1,105.16
in general payments reported to CMS, 2019-2025
14 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $196 · 2021: $188 · 2022: $37.34 · 2024: $98.31 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $176.23 | 2019-2021 | |
| Alcon Vision LLC | $144.04 | 2022-2025 | Tryptyr |
| Sun Pharmaceutical Industries INC. | $143.10 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.28 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $94.31 | 2024-2025 | Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $85.14 | 2019-2021 | |
| Coopervision INC. | $78.09 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $77.53 | 2019-2021 | |
| Alimera Sciences, INC. | $75.22 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $39.70 | 2024 | Xdemvy |
| Mallinckrodt Enterprises LLC | $38.45 | 2019 | |
| Dompe US, INC. | $14.93 | 2021 | |
| Shire North American Group INC | $14.62 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.